[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

AT&T Inc. (T) – Form 4 insider filing

On 31-Jul-2025, director Luis A. Ubinas acquired 616.6355 deferred stock units (DSUs) through the company’s Non-Employee Director Stock and Deferral Plan. The transaction is coded “A” (open-market or plan acquisition) with a reference price of $27.41 per unit. DSUs convert to a cash amount equal to one share of AT&T common stock when the director leaves the board.

After this purchase, Ubinas’ indirect holdings—maintained “By Benefit Plan”—rose to 61,524.6702 DSUs. No common shares were sold, and there were no non-derivative transactions reported. The report was signed 04-Aug-2025. Given the small size relative to current ownership and AT&T’s overall share count, the filing appears to be a routine incremental accumulation rather than a strategic signal.

Insights

Corporate Governance Analyst

TL;DR: Small, routine DSU purchase by director; neutral for valuation, mildly positive for alignment.

The acquisition of 617 DSUs ($27.41 reference price) adds less than 1 % to Mr. Ubinas’ existing 61.5 k-unit position and is immaterial versus AT&T’s float. Because DSUs settle in cash after board service, the move marginally increases economic exposure but does not tighten share supply. No sales or option exercises accompany the filing, and there is no indication of board or strategic changes. Overall impact on governance perception and market sentiment is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	17000	549936.00	43472928	08/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	08/04/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			17000	08/04/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael R Megna 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	05/07/2025	17647	471014.00
Michael R Megna 23 OLD BOND STREET, FLOOR 3 LONDON X0 WIS 4PZ	Kiniksa Pharmaceuticals International, plc	06/03/2025	15211	437330.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AT&T deferred stock units did Director Luis A. Ubinas acquire on 31-Jul-2025?

616.6355 deferred stock units were acquired.

What was the transaction code used in the Form 4 for AT&T (T)?

The filing lists transaction code “A”, indicating an acquisition.

What is Director Ubinas’ total indirect beneficial ownership after the transaction?

His indirect holdings rose to 61,524.6702 deferred stock units.

How are the deferred stock units settled under AT&T’s plan?

After board service ends, each unit is paid in cash equal to the value of one AT&T common share.